Education
About Us
Working with TipRanks
Follow Us
Abbvie (GB:0QCV)
:0QCV
0QCV Stock Chart & Stats
$227.16
$0.00(0.00%)
At close: 4:00 PM EDT
$227.16
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$159.76 - $244.49
Previous CloseN/A
Volume123.97K
Average Volume (3M)18.84K
Market Cap
$399.57B
Enterprise Value$473.40B
Total Cash (Recent Filing)$5.67B
Total Debt (Recent Filing)$68.74B
Price to Earnings (P/E)171.4
Beta0.50
Next Earnings
Feb 04, 2026EPS Estimate
3.35Last Dividend Ex-Date
Oct 15, 2025Dividend Yield4.81%
Share Statistics
EPS (TTM)1.86
Shares Outstanding1,767,384,600
10 Day Avg. Volume41,317
30 Day Avg. Volume18,841
Financial Highlights & Ratios
PEG Ratio-6.08
Price to Book (P/B)94.54
Price to Sales (P/S)5.58
P/FCF Ratio17.63
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue7.94
Enterprise Value/Gross Profit10.42
Enterprise Value/Ebitda37.21
Forecast
1Y Price Target
$248.67Price Target Upside9.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering24
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Patent ProtectionAbbVie reached a settlement delaying generic competition for Rinvoq to 2037, extending its patent protection and enhancing its market position.
Product PerformanceThe company's key immunology products, Skyrizi and Rinvoq, continue to deliver strong performance, capturing significant market share in Crohn’s disease and ulcerative colitis.
Revenue GrowthAbbVie posted a 3Q beat and raised 2025 revenue and EPS guidance, driven by strong performance of key immunology products Skyrizi and Rinvoq.
Bears Say
Aesthetics Segment WeaknessThe aesthetics franchise continues to struggle, with both Botox Cosmetic and Juvederm experiencing year-over-year declines.
Competitive Landscape ChallengesThere is debate emerging on the competitive landscape for Skyrizi/Rinvoq in light of the launch of JNJ SubQ Tremfya in IBD, and ahead of JNJ’s oral psoriasis pill expected to launch next year.
Stock Valuation ConcernsABBV's P/E appears to already account for durable, above-average growth, which may limit further stock appreciation.
AbbVie News
0QCV FAQ
What was Abbvie’s price range in the past 12 months?
Abbvie lowest share price was $159.76 and its highest was $244.49 in the past 12 months.
What is Abbvie’s market cap?
Abbvie’s market cap is $399.57B.
When is Abbvie’s upcoming earnings report date?
Abbvie’s upcoming earnings report date is Feb 04, 2026 which is in 58 days.
How were Abbvie’s earnings last quarter?
Abbvie released its earnings results on Oct 31, 2025. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.766 by $0.094.
Is Abbvie overvalued?
According to Wall Street analysts Abbvie’s price is currently Undervalued.
Does Abbvie pay dividends?
Abbvie pays a Quarterly dividend of $1.64 which represents an annual dividend yield of 4.81%. See more information on Abbvie dividends here
What is Abbvie’s EPS estimate?
Abbvie’s EPS estimate is 3.35.
How many shares outstanding does Abbvie have?
Abbvie has 1,767,384,600 shares outstanding.
What happened to Abbvie’s price movement after its last earnings report?
Abbvie reported an EPS of $1.86 in its last earnings report, beating expectations of $1.766. Following the earnings report the stock price went down -3.953%.
Which hedge fund is a major shareholder of Abbvie?
Currently, no hedge funds are holding shares in GB:0QCV
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$248.67 (9.47% Upside)
$248.67 (9.47% Upside)
Blogger Sentiment
Bullish
GB:0QCV Sentiment 70%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.81%
12-Months-Change
Fundamentals
Return on Equity
138.53%
Trailing 12-Months
Asset Growth
-6.64%
Trailing 12-Months
Company Description
Abbvie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
0QCV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
AbbVie's earnings call reflects a strong overall performance with significant growth in key therapeutic areas like immunology and neuroscience. Financial results exceeded expectations, and the company raised its full-year outlook. However, challenges persist in the aesthetics segment and Humira's sales erosion due to biosimilar competition. Despite these challenges, the company's robust pipeline and increased R&D investment underline a positive long-term outlook.View all GB:0QCV earnings summaries0QCV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
0QCV Stock 12 Month Forecast
Average Price Target
$248.67
▲(9.47% Upside)
Technical Analysis
Options Prices
Currently, No data available
---